Navigation Links
Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements
Date:2/4/2011

OSLO, Norway, Feb. 4, 2011 /PRNewswire/ -- Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its consumer trial with Allumera™, a breakthrough cosmetic treatment formulated to improve the skin's appearance.

The RevitAll study was performed with a standard cosmetic protocol and designed to confirm if treatment with Allumera™ improves skin appearance, when compared to exposure by light alone.  The study also looked into longevity of results.

This controlled, prospective study enrolled 120 women to receive three treatments, four weeks apart.  The total duration of the study was five months.  Half the study participants received Allumera™ plus light, while the remaining received light alone (control group).  Participants were monitored for three months following the last treatment to evaluate which effects were long-lasting.  The study evaluations included both objective and subjective assessments.  The objective assessments included measurement of pores, skin firmness/elasticity, skin tone (radiance/luminosity), skin surface topography and tolerability.  

At the five month evaluation, participants who received Allumera™ for one hour followed by exposure to light, showed a significant 44% reduction in the appearance of pores (p<0.001), when compared to baseline, and the difference between the two groups was statistically significant (p=0.002).  A statistically significant improvement (p<0.0001) in skin firmness and suppleness was also observed for the Allumera group when compared to the control group.  A 35% improvement in the appearance of skin tone (p<0.05) was also found, but this, however, was not statistically significant when compared to the control group.

"The results from our RevitAll study provide a solid foundation for our efforts to commer
'/>"/>

SOURCE Photocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Oct. 1, 2014 Trovagene, ... diagnostics, announced today that Eli Diamond , ... Cancer Center (MSK), presented clinical data from an ... cancer monitoring platform for the determination of oncogene ... liquid biopsy.  The results were presented to both ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
(Date:10/1/2014)... , October 1, 2014 Sophia ... Generation Sequencing (NGS) data analysis, today launches a unique ... fibrosis analysis in a single NGS experiment. The CE-IVD ... types of variants in a single NGS experiment with ... has not been possible to simultaneously analyse all relevant ...
Breaking Medicine Technology:Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 2Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 3Clinical Performance of Trovagene's Precision Cancer Monitoring Platform Presented at Second Annual International ECD Medical Symposium 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
... Ind., Nov. 3, 2011 Zimmer Holdings, Inc. (NYSE: ... Anterior Cervical Plate System at the 26th North American ... a generous graft window and narrow waist providing clinicians with ... has a low profile (less than 2mm) which clinical literature ...
... PERKASIE, Pa., Nov. 3, 2011 A new company ... customers for implantable medical devices.  US BioDesign, located in ... medical device OEM firms to broaden the company,s breadth ... founders, Tom Molz – CEO and Skott Greenhalgh – ...
Cached Medicine Technology:Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 2Zimmer Introduces inViZia™ Anterior Cervical Plate System at NASS Annual Meeting 3Newly Launched US BioDesign to Provide OEM Development/Manufacturing Services to Medical Device Customers 2
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... finding from Duke Medicine suggests that some people who ... be hard-wired to gain weight when exposed to chronic ... estimated 13 percent of people, all of whom are ... could help them reduce heart disease with simple interventions ... , "Genetic susceptibility, psychosocial stress and metabolic factors act ...
(Date:10/1/2014)... Jupiter, FL (PRWEB) October 01, 2014 ... Begley, Jr., scheduled to broadcast on Monday, October 20, ... In this episode, Innovations will go behind the scenes ... prevention programs. This segment will explore the practical help ... young adults, which teaches the warning signs of abuse, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Anti Aging ... and skin rejuvenating destination of choice, is announcing a ... October through to December. , “We’re doing this because ... possible to our top skin clinic in Toronto,” says ... do so much at Anti Aging Clinic, including laser ...
Breaking Medicine News(10 mins):Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... 2011)Approximately 10-20 percent of prostate cancer patients have a family ... that are used to evaluate the extent and aggressiveness of ... the Prostate Specific Antigen Level (PSA), Gleason score (GS) from ... However, men with a family history of prostate cancer have ...
... , WEDNESDAY, Oct. 5 (HealthDay News) -- Smokers have ... are more likely than men to suffer complications after a ... data on 3,588 patients admitted to the University of Michigan ... attack. About 24 percent of the patients were current smokers. ...
... A tracheostomy performed within the first seven days after a ... to a team of Penn State College of Medicine researchers. ... chance of surviving when admitted to the hospital. A ... neck directly into the trachea to allow unimpeded breathing. (A ...
... Therapeutics will be held from Nov. 12-16, 2011, at ... This unique conference combines the efforts of the American ... the European Organisation for the Research and Treatment of ... to focus exclusively on issues of drug development as ...
... New Tool That Helps Identify Prostate Cancer Patients with ... (October 4, 2011)After a prostate cancer patient receives radiation ... antigen, or PSA, in his blood. An increase in ... of the cancer,s return to the prostate. Fox Chase ...
... video games, already known to improve motor function in,recovering ... in intensive care units (ICU), new research from Johns,Hopkins ... Journal of Critical Care ,researchers studied the safety ... therapy in the ICU. "Patients admitted to our ...
Cached Medicine News:Health News:More aggressive treatment not necessary for men with a family history of prostate cancer 2Health News:Earlier tracheostomies result in better patient outcomes 2Health News:New tool helps identify prostate cancer patients with highest risk of death 2Health News:Practical play: Interactive video games appear valuable for ICU patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: